| |
Glasgow/poster: 48-Week Efficacy and Safety and Early CNS Tolerability of Doravirine,a Novel NNRTI, With TDF/FTC in ART-Naïve HIV-Infected Patients
|
| |
| |
Reported by Jules Levin
HIV Drug Therapy
Glasgow 2014
JM Gatell1, JO Morales-Ramirez2, DP Hagins3, M Thompson4, K Arasteh5, C Hoffmann6, S Rugina7, O Osiyemi8, S Erscoiu9, R Dretler10, C Harvey11, X Xu11, H Teppler11 for the P007 Study Team
1Hospital Clinic/IDIBAPS, University of Barcelona, Spain; 2Clinical Research Puerto Rico, San Juan, PR; 3Chatham County Health Department, Savannah, GA, USA; 4AIDS Research Consortium of Atlanta, GA, USA; 5EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 6ICH Study Center, Hamburg, Germany; 7 Spitalul Clinic de Boli Infectioase, Constanta, Romania; 8Triple O Research Institute PA, West Palm Beach, FL, USA; 9Spitalul Clinic de Boli Infectioase, Constanta, Romania; 10Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 11Merck & Co., Inc., Whitehouse Station, NJ, USA
|
|
| |
| |
|
|
|
